Citations

Clear

6274 citation(s) found for "To, Andrew".

The Miami International Evidence-based Guidelines on Minimally Invasive Pancreas Resection
Asbun, Horacio J. , Moekotte, Alma , Vissers, Frederique L., Kunzler, F. , Cipriani, Federica , D’Angelica, Michael I. , Balduzzi, Alberto , Bassi, Claudio , Björnsson, Bergþór , Boggi, Ugo , Callery, Mark P., Chiaro, Marco Del , Coimbra, Felipe José Fernández , Conrad, Claudius , Cook, Andrew , Coppola, Alessandro , Dervenis, Christos, Dokmak, Safi , Edil, Barish H. , Giulianotti, Pier Cristoforo , Hansen, Paul D., Heijde, Nicky van der , Hilst, Jony van , Hester, Caitlin A. , Hogg, Melissa E. , Jarufe, Nicolás , Jeyarajah, D. Rohan, Kim, Song Cheol, Khatkov, Igor , Kokudo, Norihiro , Kooby, David A. , Korrel, Maarten , Leon, Francisco J. de, Lluís, Núria , Lof, Sanne , Demartines, Nicolas , Merchant, Nipun B. , Molenaar, I. Quintus, Moravek, Cassadie, Mou, Yiping , Nealon, William H. , Palanivelu, Chinnusamy, Pessaux, Patrick , Pitt, Henry A. , Primrose, John N., Rawashdeh, Arab , Sanford, Dominic E. , Senthilnathan, Palanisamy, Shrikhande, Shailesh V. , Stauffer, John , Takaori, Kyoichi , Tang, Chung Ngai, Vollmer, Charles M., Wakabayashi, Go , Walsh, R. Matthew , Wang, Shin-E, Zinner, Michael J. , Wolfgang, Christopher L. , Zureikat, Amer H. , Zwart, M. , Conlon, Kevin C. , Kendrick, Michael L., Zeh, Herbert J. , Hilal, Mohammad Abu, Besselink, Marc G. , Primrose, John , Hilal, Mohammad Abu , Demartines, N , A Stauffer, John , Alseidi, Adnan A. , Edwin, Bjørn , Han, Ho-Seong , Jeyarajah, D. Rohan , Keck, Tobias , Machado, Marcel Autran C. , Martinie, John B. , Moravek, Cassadie, Nakamura, Masafumi , Palanivelu, Chinnusamy , Polanco, Patricio Marcelo , Talamonti, Marina , Wang, Shin‐E , Kendrick, Michael L. , Besselink, Marc G , Cipriani, Federica

Mayo Clinic

Annals of Surgery | September 22, 2019 | Volume: 271 | Issue: 1 | Pages: 1-14

10.1097/sla.0000000000003590 | PMID 31567509 Get It

Objective: The aim of this study was to develop and externally validate the first evidence-based guidelines on minimally invasive pancreas resection (MIPR) before and during the International Evidence-based Guidelines on Minimally Invasive Pancreas Resection (IG-MIPR) meeting in Miami (March 2019). Summary Background Data: MIPR has seen rapid development in the past decade. Promising outcomes have been reported by early adopters from high-volume centers. Subsequently, multicenter series as well as randomized controlled trials were reported; however, guidelines for clinical practice were lacking. Methods: The Scottisch Intercollegiate Guidelines Network (SIGN) methodology was used, incorporating these 4 items: systematic reviews using PubMed, Embase, and Cochrane databases to answer clinical questions, whenever possible in PICO style, the GRADE approach for assessment of the quality of evidence, the Delphi method for establishing consensus on the developed recommendations, and the AGREE-II instrument for the assessment of guideline quality and external validation. The current guidelines are cosponsored by the International Hepato-Pancreato-Biliary Association, the Americas Hepato-Pancreato-Biliary Association, the Asian-Pacific Hepato-Pancreato-Biliary Association, the European-African Hepato-Pancreato-Biliary Association, the European Association for Endoscopic Surgery, Pancreas Club, the Society of American Gastrointestinal and Endoscopic Surgery, the Society for Surgery of the Alimentary Tract, and the Society of Surgical Oncology. Results: After screening 16,069 titles, 694 studies were reviewed, and 291 were included. The final 28 recommendations covered 6 topics; laparoscopic and robotic distal pancreatectomy, central pancreatectomy, pancreatoduodenectomy, as well as patient selection, training, learning curve, and minimal annual center volume required to obtain optimal outcomes and patient safety. Conclusion: The IG-MIPR using SIGN methodology give guidance to surgeons, hospital administrators, patients, and medical societies on the use and outcome of MIPR as well as the approach to be taken regarding this challenging type of surgery.
Human Pegivirus Infection and Lymphoma Risk: A Systematic Review and Meta-analysis
Link, Brian K. , Call, Timothy G. , Ansell, Stephen M. , Liebow, Mark , Xiang, Jinhua , Nowakowski, Grzegorz S. , Famà, Angelo , Link, Brian K , Larson, Melissa C. , Habermann, Thomas M. , Feldman, Andrew L. , Maurer, Matthew J. , Slager, Susan L. , Stapleton, Jack T. , Cerhan, James R.

Mayo Clinic

Clinical Infectious Diseases | September 20, 2019 | Volume: 71 | Issue: 5 | Pages: 1221-1228

10.1093/cid/ciz940 | PMID 31671178 Get It

AbstractBackgroundHuman pegivirus (HPgV) is a single-strand RNA virus belonging to the Flaviviridae. Although no definitive association between HPgV infection and disease has been identified, previous studies have suggested an association of HPgV viremia with risk of lymphomas.MethodsWe conducted a systematic review and meta-analysis, including 1 cohort study and 14 case-control studies, assessing the association of HPgV viremia with adult lymphomas. Odds ratios (ORs) and 95% confidence intervals (CIs) were calculated using a random-effects model, overall and by geographic region and lymphoma subtype.ResultsThe overall OR for lymphoma was 2.85 (95% CI, 1.98–4.11), with statistically significantly elevated ORs observed in 8 of 15 studies. There was a small amount of heterogeneity among studies (I2 = 28.9%; Q = 18.27, P = .16), and the funnel plot provided no evidence for publication bias. The strongest association with lymphoma risk was observed for studies from Southern Europe (OR, 5.68 [95% CI, 1.98–16.3]), whereas weaker ORs (with 95% CIs) were observed for studies from North America (2.24 [1.76–2.85]), Northern Europe (2.90 [.45–18.7), and the Middle East (2.51 [.87–7.27]), but all of similar magnitude. Participants with HPgV viremia had statistically significantly increased risks (OR [95% CI]) for developing diffuse large B-cell (3.29 [1.63–6.62]), follicular (3.01 [1.95–4.63]), marginal zone (1.90 [1.13–3.18]), and T-cell (2.11 [1.17–3.89]) lymphomas, while the risk for Hodgkin lymphoma (3.53 [.48–25.9]) and chronic lymphocytic leukemia (1.45 [.45–4.66]) were increased but did not achieve statistical significance.ConclusionsThis meta-analysis supports a positive association of HPgV viremia with lymphoma risk, overall and for the major lymphoma subtypes.
Small intestinal bacterial overgrowth and nonalcoholic fatty liver disease: a systematic review and meta-analysis
Lou, Susan , Watthanasuntorn, Kanramon , Cheungpasitporn, Wisit , Lukens, Frank , Pungpapong, Surakit , Ungprasert, Patompong , Lukens, Frank J., Cheungpasitporn, Wisit , Pungpapong, Surakit , Wijarnpreecha, Karn , Kröner, Paul T. , Keaveny, Andrew P.

Mayo Clinic

European Journal of Gastroenterology & Hepatology | September 20, 2019 | Volume: 32 | Issue: 5 | Pages: 601-608

10.1097/meg.0000000000001541 | PMID 31567712 Get It

Objectives Recent studies have suggested that small intestinal bacterial overgrowth (SIBO) could be a predisposing factor for nonalcoholic fatty liver disease (NAFLD) although the results were inconsistent. This systematic review and meta-analysis was conducted with the aim to summarize all available data. Methods A comprehensive literature review was conducted utilizing MEDLINE and EMBASE databases through September 2018 to identify all studies that compared the risk of NAFLD among patients with SIBO versus those without SIBO. Effect estimates from each study were extracted and combined together using the random effect, generic inverse variance method of DerSimonian and Laird. Results A total of 10 studies with 1093 participants fulfilled the eligibility criteria and were included in the meta-analysis. A significant association between NAFLD and SIBO was observed with the pooled odds ratio of 3.82 (95% confidence interval, 1.93–7.59; I 2 65%). Funnel plot is relatively symmetric and is not suggestive of the presence of publication bias. Conclusion A significant association between NAFLD and SIBO was observed in this meta-analysis.
Summary for Clinicians: Microbiological Laboratory Testing in the Diagnosis of Fungal Infections in Pulmonary and Critical Care Practice
Hage, Chadi A. , Carmona, Eva M. , Evans, Scott E. , Ruminjo, Joseph K., Thomson, Carey C. , Carmona, Eva M , Limper, Andrew H.

Mayo Clinic

Annals of the American Thoracic Society | September 17, 2019 | Volume: 16 | Issue: 12 | Pages: 1473-1477

10.1513/annalsats.201908-582cme | PMID 31526275 Get It

Intravenous Bone Marrow Mononuclear Cells for Acute Ischemic Stroke: Safety, Feasibility, and Effect Size from a Phase I Clinical Trial
Haque, Muhammad , Zhu, Hongjian , Rowan, Paul J. , Aisiku, Imoigele P. , Juneja, Harinder S., Alderman, Susan , Barreto, Andrew D. , Suárez, José I. , Bambhroliya, Arvind , Hasan, Khader M. , Kassam, Mallikarjuna Rao, Aronowski, Jaroslaw , Gee, Adrian P. , Cox, Charles S. , Grotta, James C. , Savitz, Sean I. , Vahidy, Farhaan S , Rahbar, Mohammad H. , Lee, Dean Anthony , Grotta, James C

Mayo Clinic

Stem Cells | September 17, 2019 | Volume: 37 | Issue: 11 | Pages: 1481-1491

10.1002/stem.3080 | PMID 31529663 Get It

AbstractCellular therapy is a promising investigational modality to enhance poststroke recovery. We conducted a single-arm, phase I clinical trial to determine the safety and feasibility of intravenous (IV) administration of autologous bone marrow mononuclear cells (MNCs) after acute ischemic stroke (AIS). Patients with moderate severity of AIS underwent bone marrow harvest followed by IV reinfusion of MNCs within 24–72 hours of onset. A target dose of 10 million cells per kilogram was chosen based on preclinical data. Patients were followed up daily during hospitalization and at 1, 3, 6, 12, and 24 months for incidence of adverse events using laboratory, clinical (12 months), and radiological (24 months) parameters. The trial was powered to detect severe adverse events (SAEs) with incidences of at least 10% and planned to enroll 30 patients. Primary outcomes were study-related SAEs and the proportion of patients successfully completing study intervention. A propensity score-based matched control group was used for the estimation of effect size (ES) for day-90 modified Rankin score (mRS). There were no study-related SAEs and, based on a futility analysis, enrolment was stopped after 25 patients. All patients successfully completed study intervention and most received the target dose. Secondary analysis estimated the ES to be a reduction of 1 point (95% confidence interval: 0.33–1.67) in median day-90 mRS for treated patients as compared with the matched control group. Bone marrow harvest and infusion of MNCs is safe and feasible in patients with AIS. The estimated ES is helpful in designing future randomized controlled trials. Stem Cells 2019;37:1481–1491
Probability of Bladder Augmentation, Diversion and Clean Intermittent Catheterization in Classic Bladder Exstrophy: A 36-Year, Multi-Institutional, Retrospective Cohort Study
Szymanski, Konrad M. , Fuchs, Molly , McLeod, Daryl J. , Strine, Andrew C., VanderBrink, Brian A. , Yerkes, Elizabeth B. , Gargollo, Patricio C. , Rosoklija, Ilina , Whittam, Benjamin M.

Mayo Clinic

Journal of Urology | September 17, 2019 | Volume: 202 | Issue: 6 | Pages: 1256-1262

10.1097/ju.0000000000000552 | PMID 31526259 Get It

Practice guideline update summary: Acute treatment of migraine in children and adolescents
Pringsheim, Tamara , Holler‐Managan, Yolanda, Potrebic, Sonja , Billinghurst, Lori , Gloss, David , Hershey, Andrew D. , Licking, Nicole, Sowell, Michael, Victorio, M. Cristina, Gersz, Elaine , Leininger, Emily, Zanitsch, Heather, Yonker, Marcy, Mack, Kenneth J. , Mack, Kenneth, Hershey, Andrew , Oskoui, Maryam , Pringsheim, Tamara

Mayo Clinic

Headache: The Journal of Head and Face Pain | September 17, 2019 | Volume: 59 | Issue: 8 | Pages: 1158-1173

10.1111/head.13628 | PMID 31529481 Get It

Objective To provide evidence‐based recommendations for the acute symptomatic treatment of children and adolescents with migraine. Methods We performed a systematic review of the literature and rated risk of bias of included studies according to the American Academy of Neurology classification of evidence criteria. A multidisciplinary panel developed practice recommendations, integrating findings from the systematic review and following an Institute of Medicine‐compliant process to ensure transparency and patient engagement. Recommendations were supported by structured rationales, integrating evidence from the systematic review, related evidence, principles of care, and inferences from evidence. Results There is evidence to support the efficacy of the use of ibuprofen, acetaminophen (in children and adolescents), and triptans (mainly in adolescents) for the relief of migraine pain, although confidence in the evidence varies between agents. There is high confidence that adolescents receiving oral sumatriptan/naproxen and zolmitriptan nasal spray are more likely to be headache free at 2 hours than those receiving placebo. No acute treatments were effective for migraine‐related nausea or vomiting; some triptans were effective for migraine‐related phonophobia and photophobia. Recommendations Recommendations for the treatment of acute migraine in children and adolescents focus on the importance of early treatment, choosing the route of administration best suited to the characteristics of the individual migraine attack, and providing counselling on lifestyle factors that can exacerbate migraine, including trigger avoidance and medication overuse.
Practice guideline update summary: Pharmacologic treatment for pediatric migraine prevention
Pringsheim, Tamara , Billinghurst, Lori , Potrebic, Sonja , Gersz, Elaine , Gloss, David , Holler‐Managan, Yolanda, Leininger, Emily, Licking, Nicole, Mack, Kenneth J. , Powers, Scott W. , Sowell, Michael, Victorio, M. Cristina, Yonker, Marcy, Zanitsch, Heather, Hershey, Andrew D. , Mack, Kenneth, Hershey, Andrew , Oskoui, Maryam

Mayo Clinic

Headache: The Journal of Head and Face Pain | September 17, 2019 | Volume: 59 | Issue: 8 | Pages: 1144-1157

10.1111/head.13625 | PMID 31529477 Get It

Objective To provide updated evidence‐based recommendations for migraine prevention using pharmacologic treatment with or without cognitive behavioral therapy in the pediatric population. Methods The authors systematically reviewed literature from January 2003 to August 2017 and developed practice recommendations using the American Academy of Neurology 2011 process, as amended. Results Fifteen class I‐III studies on migraine prevention in children in adolescents met inclusion criteria. There is insufficient evidence to determine if children and adolescents receiving divalproex, onabotulinumtoxinA, amitriptyline, nimodipine and flunarizine are more or less likely than those receiving placebo to have a reduction in headache frequency. Children with migraine receiving propranolol are possibly more likely than those receiving placebo to have an at least 50% reduction in headache frequency. Children and adolescents receiving topiramate and cinnarizine are probably more likely than those receiving placebo to have a decrease in headache frequency. Children with migraine receiving amitriptyline plus cognitive behavioral therapy are more likely than those receiving amitriptyline plus headache education to have a reduction in headache frequency. Recommendations The majority of randomized controlled trials studying the efficacy of preventive medications for pediatric migraine fail to demonstrate superiority to placebo. Recommendations for the prevention of migraine in children include counseling on lifestyle and behavioral factors that influence headache frequency, and assessment and management of comorbid disorders associated with headache persistence. Clinicians should engage in shared decision making with patients and caregivers regarding the use of preventive treatments for migraine, including discussion of the limitations in the evidence to support pharmacologic treatments.
TGFβ-induced fibroblast activation requires persistent and targeted HDAC-mediated gene repression
Jones, Dakota L. , Haak, Andrew J. , Caporarello, Nunzia , Choi, Kyoung Moo , Ye, Zhenqing, Yan, Huihuang , Varelas, Xaralabos , Ördög, Tamás , Ligresti, Giovanni , Tschumperlin, Daniel J. , Choi, Kyoung M, Varelas, Xaralabos , Caporarello, Nunzia

Mayo Clinic

Journal of Cell Science | September 16, 2019 | Volume: 132 | Issue: 20 | Pages: No page available

10.1242/jcs.233486 | PMID 31527052 Get It

ABSTRACT Tissue fibrosis is a chronic disease driven by persistent fibroblast activation that has recently been linked to epigenetic modifications. Here, we screened a small library of epigenetic small-molecule modulators to identify compounds capable of inhibiting or reversing TGFβ-mediated fibroblast activation. We identified pracinostat, an HDAC inhibitor, as a potent attenuator of lung fibroblast activation and confirmed its efficacy in patient-derived fibroblasts isolated from fibrotic lung tissue. Mechanistically, we found that HDAC-dependent transcriptional repression was an early and essential event in TGFβ-mediated fibroblast activation. Treatment of lung fibroblasts with pracinostat broadly attenuated TGFβ-mediated epigenetic repression and promoted fibroblast quiescence. We confirmed a specific role for HDAC-dependent histone deacetylation in the promoter region of the anti-fibrotic gene PPARGC1A (PGC1α) in response to TGFβ stimulation. Finally, we identified HDAC7 as a key factor whose siRNA-mediated knockdown attenuates fibroblast activation without altering global histone acetylation. Together, these results provide novel mechanistic insight into the essential role HDACs play in TGFβ-mediated fibroblast activation via targeted gene repression.